-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RQXapoCczBGQBXe0k/OvnTRjSpB9lchKJ5imbLg29/auUPnXQh2vb3ztxxLQ29Tq YvvVgrGOO1EbAoF9eyWPmQ== 0001144204-06-047007.txt : 20061114 0001144204-06-047007.hdr.sgml : 20061114 20061114091001 ACCESSION NUMBER: 0001144204-06-047007 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060930 FILED AS OF DATE: 20061114 DATE AS OF CHANGE: 20061114 EFFECTIVENESS DATE: 20061114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 061211517 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v057461_13f-hr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: September 30, 2006 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 17th Floor -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. November 14, 2006 - -------------------------- --------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 67 ----------- Form 13F Information Table Entry Value: 859,414 ----------- (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ----------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 10,776 1,247,264 SH SOLE 1,247,264 Adeza Biomedical Corp. COM 006864102 2,447 149,107 SH SOLE 149,107 Adolor Corp. COM 00724X102 19,017 1,371,092 SH SOLE 1,371,092 Allos Therapeutics Inc. COM 019777101 19,974 5,298,238 SH SOLE 5,298,238 Altus Pharmaceuticals Inc. COM 02216N105 3,695 231,401 SH SOLE 231,401 Amylin Pharmaceuticals Inc. COM 032346108 78,445 1,780,016 SH SOLE 1,780,016 Anesiva Inc. COM 21872P501 426 62,800 SH SOLE 62,800 Anormed Inc. COM 035910108 119,056 9,411,500 SH SOLE 9,411,500 Aradigm Corp. COM 038505301 168 100,000 SH SOLE 100,000 Arena Pharmaceuticals Inc. COM 040047102 3,658 305,329 SH SOLE 305,329 Array Biopharma Inc. COM 04269X105 2,237 262,595 SH SOLE 262,595 Atherogenics Inc. COM 047439104 659 50,036 SH SOLE 50,036 Autoimmune Inc. COM 052776101 29 26,100 SH SOLE 26,100 Biocryst Pharmaceuticals Inc. COM 09058V103 22,132 1,774,838 SH SOLE 1,774,838 Biomarin Pharmaceutical Inc. COM 09061G101 4,407 309,671 SH SOLE 309,671 Cerus Corp. COM 157085101 4,128 743,802 SH SOLE 743,802 Coley Pharmaceutical Group Inc. COM 19388P106 6,261 548,266 SH SOLE 548,266 Columbia Labaratories Inc. COM 197779101 3,124 902,761 SH SOLE 902,761 Cotherix Inc. COM 22163T103 2,205 312,300 SH SOLE 312,300 Critical Therapeutics Inc. COM 22674T105 822 342,384 SH SOLE 342,384 Cubist Pharmaceuticals Inc. COM 229678107 3,566 164,030 SH SOLE 164,030 Curis Inc. COM 231269101 37 26,800 SH SOLE 26,800 Cyclacel Pharmaceuticals COM 23254L108 3,429 714,286 SH SOLE 714,286 Cyclacel Pharmaceuticals Pfd. Conv. Ex 6% PFD CONV EX 23254L207 435 95,500 SH SOLE 95,500 Cytokinetics Inc. COM 23282W100 632 98,300 SH SOLE 98,300 Genomic Health Inc. COM 37244C101 19,018 1,315,202 SH SOLE 1,315,202 GTX Inc. COM 40052B108 137 14,800 SH SOLE 14,800 Halozyme Therapeutics Inc. COM 40637H109 1,325 500,000 SH SOLE 500,000 Icagen Inc. COM 45104P104 105 113,825 SH SOLE 113,825 Idera Pharmaceuticals Inc. COM 45168K108 9,318 2,272,725 SH SOLE 2,272,725 Incyte Corp. COM 45337C102 14,019 3,314,070 SH SOLE 3,314,070 Inhibitex Inc. COM 45719T103 102 66,430 SH SOLE 66,430 Intermune Inc. COM 45884X103 8,440 514,019 SH SOLE 514,019 Isis Pharmaceuticals Inc. COM 464330109 135 18,859 SH SOLE 18,859 Ligand Pharmaceuticals Inc. CL B 53220K207 385 38,357 SH SOLE 38,357 Medarex Inc. COM 583916101 10,540 980,434 SH SOLE 980,434 Medimmune Inc. COM 584699102 3,998 136,600 SH SOLE 136,600 Metabasis Therapeutics Inc. COM 59101M105 13,593 2,418,735 SH SOLE 2,418,735 Monogram Biosciences Inc. COM 60975U108 75 49,275 SH SOLE 49,275 Myriad Genetics Inc. COM 62855J104 36,619 1,485,545 SH SOLE 1,485,545 Neopharm Inc. COM 640919106 4,034 831,721 SH SOLE 831,721 Neose Technologies Inc. COM 640522108 998 504,150 SH SOLE 504,150 Neurogen Corp. COM 64124E106 35,897 5,325,999 SH SOLE 5,325,999 Nuvelo Inc. COM 67072M301 24,691 1,353,687 SH SOLE 1,353,687 Pharmacyclics Inc. COM 716933106 1,009 207,518 SH SOLE 207,518 Pozen Inc. COM 73941U102 4,293 333,837 SH SOLE 333,837 Renovis Inc. COM 759885106 4,624 336,037 SH SOLE 336,037 Replidyne Inc. COM 76028W107 2,353 250,000 SH SOLE 250,000 Seattle Genetics Inc. COM 812578102 28,599 5,884,589 SH SOLE 5,884,589 Spectrum Pharmaceuticals Inc. COM 84763A108 3,107 592,901 SH SOLE 592,901 Sunesis Pharmaceuticals Inc. COM 867328502 5,704 1,127,214 SH SOLE 1,127,214 Tapestry Pharmaceuticals Inc. COM 876031204 4,160 2,000,000 SH SOLE 2,000,000 Telik Inc. COM 87959M109 246 13,800 SH SOLE 13,800 Theravance Inc. COM 88338T104 11,110 410,869 SH SOLE 410,869 Threshold Pharma COM 885807107 2,480 965,034 SH SOLE 965,034 Trimeris Inc. COM 896263100 31,701 3,602,369 SH SOLE 3,602,369 Vertex Pharmaceuticals Inc. COM 92532F100 71,177 2,115,206 SH SOLE 2,115,206 Viropharma Inc. COM 928241108 73,114 6,007,705 SH SOLE 6,007,705 Xenoport Inc. COM 98411C100 7,799 382,861 SH SOLE 382,861 Zymogenetics Inc. COM 98985T109 7,920 469,444 SH SOLE 469,444 Alexion Pharmaceuticals Notes 1.375% 2/01/2012 CONV BONDS 015351AF6 32,444 25,800,000 PRN SOLE 25,800,000 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 13,376 9,000,000 PRN SOLE 9,000,000 Biomarin Pharmaceuticals Notes 2.5% 3/29/2013 CONV BONDS 09061GAC5 20,390 18,600,000 PRN SOLE 18,600,000 Decode Genetics Notes 3.5% 4/15/2011 CONV BONDS 243586AB0 2,306 3,000,000 PRN SOLE 3,000,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 14,416 19,000,000 PRN SOLE 19,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 7,852 8,500,000 PRN SOLE 8,500,000 Medarex Inc Notes 2.25% 5/15/2011 CONV BONDS 583916AG6 14,040 13,500,000 PRN SOLE 13,500,000
-----END PRIVACY-ENHANCED MESSAGE-----